TOG Review (RCOG Journal)

MRCOG Part 2

Antenatal Care

Management of cytomegalovirus infection in pregnancy

Key Statistics

  • 0.48% — cCMV prevalence, high-income countries
  • 8 g/day — Valaciclovir dose (2 g/6 h)
  • 71% — Reduction in vertical transmission

Don't-miss facts

  1. Take an index sample (IgM + IgG) after reported exposure; if both negative repeat at 4 weeks. Always test the stored booking sample (IgM, IgG, avidity) when index IgM is positive

  2. AI <30% = infection <3 months ago; AI >60% = >3 months ago (likely preconceptual, cautiously reassure)

  3. Valaciclovir 8 g/day (2 g/6 h) for primary infection in first half of pregnancy → 71% reduction in vertical transmission; stop after negative amniocentesis at 21–22 weeks; monitor renal function (1.7% acute renal failure)

  4. Amniocentesis timing: >7 weeks post-infection AND >21 weeks. Miscarriage risk 0.30%; third-trimester preterm birth risk 1.2%. Still 3–8% CMV positive at birth despite negative amniocentesis

  5. Confirmed fetal CMV: ultrasound every 2–4 weeks + fetal brain MRI 28–32 weeks. Normal both = reassuring but 17% residual SNHL risk

  6. Termination: ground C before 24 weeks; ground E at any gestation with severe ultrasound abnormalities + positive amniocentesis (MDT review)

  7. Neonate: saliva/urine CMV PCR within 3 weeks of birth; valganciclovir 6 mg/kg BD within the first month of life

  8. Breastfeeding is safe and recommended in cCMV; but up to 20% of preterm/VLBW infants acquire postnatal CMV via breast milk — consider pasteurisation. Wait ≥1 year before next pregnancy after an affected baby

Red flags on scan — think CMV

FGR <3rd centile Hydrops / ascites Brain abnormalities Liver calcifications

Isolated polyhydramnios — no CMV serology Isolated echogenic bowel — only 1.4% cCMV

Numbers to know

cCMV prevalence 0.48% high-income (1 in 200 live births); 1.42% low/middle-income UK CMV IgG seroprevalence 49%; in pregnancy 50–60%; seroconversion 1–7%/year Transmission: 25–45% / 45% / 47–78% by trimester; non-primary 1.4%; primary risk 4× higher 10–15% symptomatic at birth; mortality 5%; 8–18% of asymptomatic develop sequelae; 7 in 10 normal neurodevelopment Fetal MRI: temporal ↑T2 signal 14% SNHL; temporal/occipital cysts 25%; migrational disorder/cerebellar hypoplasia 67% UK cost £732 million/year; only 33% of UK women aware of CMV

Don't say ‘TORCH screen’

Blanket term for heterogeneous pathogens; ‘negative TORCH screen’ hides which pathogens were tested and the IgG/IgM profile. Specify the test and result. Universal CMV screening not recommended in the UK; review serology jointly with a virologist/microbiologist.

Abbreviation Key

  • CMV — cytomegalovirus
  • MRI — magnetic resonance imaging
  • cCMV — congenital cytomegalovirus
  • CNS — central nervous system
  • SNHL — sensorineural hearing loss
  • NPV / PPV — negative / positive predictive value
  • AI — avidity index
  • TORCH — toxoplasmosis, rubella, cytomegalovirus, herpes
  • PCR — polymerase chain reaction
  • ISUOG — International Society of Ultrasound in Obstetrics and Gynaecology
  • IgG / IgM — immunoglobulin G / immunoglobulin M
  • MDT — multidisciplinary team
  • HHV-5 — human herpesvirus 5
  • IV — intravenous

Source: Kalogeropoulou M-S, Beardsall K, Andersson M, Ioannou C. Management of cytomegalovirus infection in pregnancy. The Obstetrician & Gynaecologist 2025;27:207–218. doi:10.1111/tog.12987

MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).

Included with a Pass Package

  • Audio overview of this guideline
  • Practice questions drawn from it
  • AI tutor answers grounded in its text
  • Your own annotations
Start free